Literature DB >> 11994394

Serum adiponectin and leptin levels in patients with lipodystrophies.

Wasim A Haque1, Iichiro Shimomura, Yuji Matsuzawa, Abhimanyu Garg.   

Abstract

Lipodystrophies are characterized by selective but variable loss of body fat and metabolic complications of insulin resistance. We hypothesized that reduced synthesis and secretion of adipocyte-specific proteins may be related to the metabolic complications of lipodystrophy. Therefore, we compared fasting serum concentrations of adiponectin and leptin, in 18 patients with congenital generalized lipodystrophy (CGL), 11 with acquired generalized lipodystrophy (AGL), 46 with familial partial lipodystrophy-Dunnigan variety (FPLD) and 18 with acquired partial lipodystrophy (APL) and studied their relationship to metabolic parameters. Patients with CGL and AGL had markedly reduced serum adiponectin levels compared to those with FPLD and APL (median [range]: 1.5 [0.4-7.5], 3.2 [0.6-7.7], 6.9 [1.9-23.2] and 7.9 [3.1-13.3] microg/mL, respectively, p < 0.0001); the same trend was noted for serum leptin levels (0.63 [0.05-3.7], 2.18 [0.05-11.30], 2.86 [0.23-9.00] and 6.24 [1.21-10.4] ng/mL, respectively, p < 0.0001). Serum adiponectin levels correlated negatively with fasting serum triglycerides (r = -0.6, p < 0.001) and insulin levels (r = -0.5, p < 0.0001) and positively with serum high-density lipoprotein cholesterol levels (r = 0.5, p < 0.001). Serum adiponectin levels were lower in patients with diabetes compared to non-diabetic subjects (3.0 vs. 7.1 microg/mL, p < 0.001). Our results indicate that serum adiponectin and leptin levels are extremely low in patients with generalized lipodystrophies and may be related to severe insulin resistance and its metabolic complications in lipodystrophies.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11994394     DOI: 10.1210/jcem.87.5.8624

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  94 in total

Review 1.  Lipoatrophic diabetes and other related syndromes.

Authors:  Elif Arioglu Oral
Journal:  Rev Endocr Metab Disord       Date:  2003-03       Impact factor: 6.514

2.  Effects of the physical form of the diet on food intake, growth, and body composition changes in mice.

Authors:  Lin Yan; Gerald F Combs; Lana C DeMars; LuAnn K Johnson
Journal:  J Am Assoc Lab Anim Sci       Date:  2011-07       Impact factor: 1.232

Review 3.  Lipodystrophy: pathophysiology and advances in treatment.

Authors:  Christina G Fiorenza; Sharon H Chou; Christos S Mantzoros
Journal:  Nat Rev Endocrinol       Date:  2010-11-16       Impact factor: 43.330

4.  Clinical effects of long-term metreleptin treatment in patients with lipodystrophy.

Authors:  Jean L Chan; Karen Lutz; Elaine Cochran; Wenying Huang; Yvette Peters; Christian Weyer; Phillip Gorden
Journal:  Endocr Pract       Date:  2011 Nov-Dec       Impact factor: 3.443

5.  Adipokines and the insulin resistance syndrome in familial partial lipodystrophy caused by a mutation in lamin A/C.

Authors:  S P Y Wong; M Huda; P English; A Bargiota; J P H Wilding; A Johnson; R Corrall; J H Pinkney
Journal:  Diabetologia       Date:  2005-11-17       Impact factor: 10.122

Review 6.  What the genetics of lipodystrophy can teach us about insulin resistance and diabetes.

Authors:  Camille Vatier; Guillaume Bidault; Nolwenn Briand; Anne-Claire Guénantin; Laurence Teyssières; Olivier Lascols; Jacqueline Capeau; Corinne Vigouroux
Journal:  Curr Diab Rep       Date:  2013-12       Impact factor: 4.810

7.  Bone imaging findings in genetic and acquired lipodystrophic syndromes: an imaging study of 24 cases.

Authors:  Stephanie Teboul-Coré; Caroline Rey-Jouvin; Anne Miquel; Camille Vatier; Jacqueline Capeau; Jean-Jacques Robert; Thao Pham; Olivier Lascols; Francis Berenbaum; Jean-Denis Laredo; Corinne Vigouroux; Jérémie Sellam
Journal:  Skeletal Radiol       Date:  2016-09-08       Impact factor: 2.199

Review 8.  Phenotypic and Genetic Characteristics of Lipodystrophy: Pathophysiology, Metabolic Abnormalities, and Comorbidities.

Authors:  Baris Akinci; Rasimcan Meral; Elif Arioglu Oral
Journal:  Curr Diab Rep       Date:  2018-11-08       Impact factor: 4.810

9.  The effects of recombinant human leptin on visceral fat, dyslipidemia, and insulin resistance in patients with human immunodeficiency virus-associated lipoatrophy and hypoleptinemia.

Authors:  Kathleen Mulligan; Hootan Khatami; Jean-Marc Schwarz; Giorgos K Sakkas; Alex M DePaoli; Viva W Tai; Michael J Wen; Grace A Lee; Carl Grunfeld; Morris Schambelan
Journal:  J Clin Endocrinol Metab       Date:  2009-01-27       Impact factor: 5.958

10.  Hypothyroidism in rats decreases peripheral glucose utilisation, a defect partially corrected by central leptin infusion.

Authors:  P Cettour-Rose; C Theander-Carrillo; C Asensio; M Klein; T J Visser; A G Burger; C A Meier; F Rohner-Jeanrenaud
Journal:  Diabetologia       Date:  2005-03-09       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.